Loading...

IMRX IMMUNEERING CORP Product Launches 8-K Filing

MMNR

MRX

IMMUNEERING CORP

(IMRX)

2025 8-K

Show Summary

Summary

Clinical Trials

Financial Statements

Financial Results

Clinical Trial Update

Clinical Trial Update

Financial Results

Director Appointment

Clinical Trial Update

Financial Results Announcement

Annual Meeting of Stockholders

Repricing of Options

Appointment of Director

Financial Results Announcement

Amendments to Bylaws

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering

Results of Operations and F...

Financial Results Announcement

External Links:

Immuneering Corp reported interim results from its Phase 1/2a clinical trials for IMM-1-104 and IMM-6-415, showing promising disease control rates and safety profiles in patients with advanced solid tumors, including an 86% disease control rate in one trial and 100% target lesion reduction in another.

AI Assistant

IMMUNEERING CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.